Evidence map›Paper›PMID 34628584›Full record

ArticleDermatology and therapy2021

Response to the Letter to the Editor Regarding "Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis".

Kyle Fahrbach, Jialu Tarpey, Evelien Bergrath Washington, Rachel Hughes, Howard Thom, Maureen P Neary, Amy Cha, Robert Gerber, Joseph C Cappelleri

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Kyle FahrbachEvidence Synthesis, Modeling and Communication, Evidera, 500 Totten Pond Road, Fifth Floor, Waltham, MA, 02451, USA. kyle.fahrbach@evidera.com.
Jialu TarpeyEvidence Synthesis, Modeling and Communication, Evidera, 500 Totten Pond Road, Fifth Floor, Waltham, MA, 02451, USA.
Evelien Bergrath WashingtonEvidence Synthesis, Modeling and Communication, Evidera, 500 Totten Pond Road, Fifth Floor, Waltham, MA, 02451, USA.
Rachel HughesEvidence Synthesis, Modeling and Communication, Evidera, 500 Totten Pond Road, Fifth Floor, Waltham, MA, 02451, USA.
Howard ThomBristol Medical School: Population Health Sciences, University of Bristol, 1-5 Whiteladies Road, Bristol, BS8 1NU, UK.
Maureen P NearyInflammation and Immunology, Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Amy ChaInflammation and Immunology, Pfizer Inc., 235 East 42nd Street, New York, NY, 10017, USA.
Robert GerberGlobal Biometrics and Data Management (Statistics), Pfizer Inc., 445 Eastern Point Road, Groton, CT, 06340, USA.
Joseph C CappelleriGlobal Biometrics and Data Management (Statistics), Pfizer Inc., 445 Eastern Point Road, Groton, CT, 06340, USA.
Pfizer (United States) · USUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Atopic dermatitisCrisaboroleNetwork meta-analysisSystematic literature review

Identifiers

PMID34628584
PMCPMC8611131
OpenAlexW3205989780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.